Gain Therapeutics Reports 12-Month Data, Plans Phase 2 for Q1 2027
Gain Therapeutics announced 12-month open-label rexaceract data showing stable MDS-UPDRS motor scores and plans to initiate a Phase 2 trial in Q1 2027.
Gain Therapeutics announced 12-month open-label rexaceract data showing stable MDS-UPDRS motor scores and plans to initiate a Phase 2 trial in Q1 2027.